Omeros Corp (OMER)
NASDAQ:OMER
Earnings Data
Report Date
May 20, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.58Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by two transformative events: the zaltenibart transaction with Novo Nordisk (large upfront payment, milestones and royalties) and FDA approval plus early commercial traction for YARTEMLEA. Financially, Q4 showed a swing to GAAP net income and robust non-GAAP profitability, materially improved cash position and eliminated several near-term debt obligations. Early launch metrics (payer approvals, rapid delivery, per-vial pricing and initial formulary wins) and pipeline progress add to the constructive outlook. Key risks include noncash volatility from embedded derivative mark-to-market adjustments, remaining 2029 convertible note exposure, incomplete formulary penetration (still early), and a regulatory request delaying one external program. Overall, highlights outweigh the lowlights, with commercialization execution and the Novo transaction materially de-risking the company’s near-term prospects.Company Guidance
Major Asset Sale to Novo Nordisk
Closed asset purchase and license for zaltenibart with Novo Nordisk, receiving $240M upfront, $100M in achievable near-term milestones, eligibility for $410M in development/approval milestones and up to $1.3B in sales/commercial milestones (total deal value up to $2.1B). Omeros retains MASP-3 small molecule rights and will receive tiered royalties up to the high teens. A transition services agreement (TSA) provides reimbursement for employee costs and inventories.
FDA Approval and Commercial Launch of YARTEMLEA (narsoplimab)
FDA approved YARTEMLEA for TA-TMA (first and only approved treatment) for adults and children ≥2 years. No box warning, no REMS, no required vaccinations. Field force fully deployed; distributors supplied within first 3 weeks of January and first sales followed shortly thereafter. Per-vial price ≈ $36,000; median utilization in trials/expanded access was 8–10 vials per course (approximate per-course drug cost $288K–$360K).
Early Launch Traction and Payer Access
Focused commercial efforts on top 80 transplant centers (represent ~80% of U.S. annual stem cell transplants). P&T committee approvals achieved at 50% of top 10 centers, 40% of top 20, 35% of top 40 and ~30% of top 80 centers. Third-party payers have approved 100% of pre-authorization requests to date.
Significant Q4 Financial Improvements and Non-GAAP Profitability
Reported Q4 2025 net income of $86.5M ($1.22/share) versus a Q3 net loss of $30.9M ($0.47 loss). Q4 included a $237.6M net gain from the zaltenibart transaction. Excluding a $136M noncash mark-to-market charge, non-GAAP adjusted net income was $222.5M and non-GAAP adjusted income per share was $3.14.
Stronger Balance Sheet and Debt Reduction
As of 12/31/25, cash and investments totaled $171.8M, an increase of $135.7M from 9/30/25. Used upfront proceeds to repay a $67.1M secured term loan and the $17.1M principal on 2026 convertible notes; remaining debt consists of $70.8M principal of 2029 convertible notes (matures June 2029).
Commercial Execution and Rapid Delivery Capability
Distribution and logistics established to deliver YARTEMLEA within 24 hours of order to both hospital and outpatient settings. Field support includes account managers, market access leads, MSLs and reimbursement support to expedite P&T and prior authorization processes.
Progress in Pipeline Beyond Complement Franchise
PDE7 program (OMS527) for cocaine use disorder funded by NIDA; T-CAT pathogen-targeting platform showing in vivo efficacy against MDROs with patents filed and publication pending; OncotoX-AML IND-enabling studies underway with strong preclinical efficacy (up to 99% reversible myeloid progenitor cell killing in NHP pilot) and first-in-human planned for late next year.
OMER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OMER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $10.56 | $12.08 | +14.39% |
Nov 13, 2025 | $6.28 | $7.87 | +25.32% |
Aug 14, 2025 | $4.12 | $4.41 | +7.04% |
May 15, 2025 | $3.95 | $3.21 | -18.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Omeros Corp (OMER) report earnings?
Omeros Corp (OMER) is schdueled to report earning on May 20, 2026, After Close (Confirmed).
What is Omeros Corp (OMER) earnings time?
Omeros Corp (OMER) earnings time is at May 20, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OMER EPS forecast?
Currently, no data Available